# US 2006/0069027 A1 · Inhibitors of hepatitis C virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069027 A1
- Document ID: US20060069027A1
- Status: Published application
- Kind: A1
- Application number: 11/235,672
- Filed: 2005-09-26
- Published: 2006-03-30
- Earliest claimed: 2004-09-29
- Assignees: The Administrators of the Tulane Educational Fund; The Rockefeller University
- Inventors: Robert Garry; Jane McKeating
- Web page: https://patentgrep.com/patent/US20060069027A1

## CPC

- C07K 14/005: from viruses
- A61K 38/162: {from virus}
- A61K 39/12: Viral antigens
- A61K 39/29: Hepatitis virus
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins that are necessary for early steps in HCV infection. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by hepatitis C virus and related viruses.

## Claims

### Claim 1

A pharmaceutical composition comprising one or more peptides selected from the group consisting of:
a) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:6;
b) a peptide homologous to any one of SEQ ID NO:1 to SEQ ID NO:6 from another hepatitis C virus strain or from hepatitis GB virus; and
c) a peptide functionally equivalent to any one of SEQ ID NO:1 to SEQ ID NO:6, wherein the functionally equivalent peptide is identical to at least one of SEQ ID NO:1 to SEQ ID NO:6 except that one or more amino acid residues has been substituted with a homologous amino acid, resulting in a functionally silent change, or one or more amino acids has been deleted.

### Claim 2

A pharmaceutical composition comprising at least one peptide selected from one or more of the following:
a) a peptide having the amino acid sequence one or more of SEQ ID NO:1 to SEQ ID NO:6, wherein the N-terminal moiety is an amino group and the C-terminal moiety is a carboxyl group;
b) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:6, wherein the N-terminal moiety is not an amino group and/or the C-terminal moiety is not a carboxyl group, wherein in place of an amino moiety the N-terminal moiety is selected from the group consisting of: an acetyl group, a hydrophobic group, carbobenzoxyl group, dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group, and/or wherein in place of a carboxyl moiety the C-terminal moiety is selected from the group consisting of an amido group, a hydrophobic group, t-butyloxycarbonyl group or a macromolecular group;
c) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:6, wherein at least one bond linking adjacent amino acid residues is a non-peptide bond;
d) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:6, wherein at least one amino acid residue is in the D-isomer configuration;
e) a peptide as in part “a)” or “b)” except that at least one amino acid has been substituted for by a different amino acid; or
f) a functional fragment of a peptide as set out in any of parts “a)” to “e)”, having at least 3 contiguous nucleotides of any one of SEQ ID NO:1 to SEQ ID NO:42.

### Claim 3 (depends on 2)

The composition of claim 2 wherein at least one peptide has an amino acid sequence is selected from one or more of the group consisting of SEQ ID NO:1, 2, 3, 4, 5 and 6.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the terminal moiety on the N-terminal amino acid is an acetyl group, a hydrophobic group a carbobenzoxyl group, a dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group; and/or the terminal moiety on C-terminal amino acid is a hydrophobic group, a t-butyloxycarbonyl group or a macromolecular group.

### Claim 5 (depends on 3)

The composition of claim 3 wherein the terminal moiety on the N-terminal amino acid is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate; and/or the terminal moiety on the C-terminal amino acid is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate.

### Claim 6 (depends on 3)

The composition of claim 3 wherein at least one bond is a non-peptide bond selected from the group consisting of an imido bond, an ester bond, a hydrazine bond, a semicarbazoide bond and an azo bond.

### Claim 7

The composition of 3 wherein at least one amino acid is a D-isomer amino acid.

### Claim 8 (depends on 3)

The composition of claim 3 wherein terminal moiety on the N-terminal amino acid group is an amino group and the terminal moiety on the C-terminal amino acid is a carboxyl group.

### Claim 9 (depends on 8)

The composition of claim 8 wherein the peptide is selected from one or more of the group consisting of SEQ ID NO:1, 2, 3, 4, 5, and 6.

### Claim 10 (depends on 1)

The composition of claim 1 where in at least one peptide is selected from the group of peptides having a sequence selected from the sequences of SEQ ID NO:7-42.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating or preventing hepatitis C virus infection comprising administering to the patient an effective amount of a pharmaceutical composition according to any of claims 1-10.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A substantially purified antibody specific for a peptide as described in any of claims 1-10.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11)

A method of treating or preventing hepatitis C virus infection comprising administering to a patient one or more peptides according to any of claims 1-9 and/or an antibody according to claim 11 and/or one or more peptides and/or one or more antibodies targeted to inhibiting the membrane fusion step mediated by hepatitis C virus envelope protein 1.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 13)

The method of claim 13, wherein the combination of the compounds from claims 1-9 and/or 11 with the peptides and/or antibodies that inhibit fusion mediated by hepatitis C virus envelope protein 1 is synergistic in preventing or inhibiting HCV infection.

### Claim 15

A peptide having the sequence of any one of SEQ ID NO:1-6 or an inhibitory portion thereof.

### Claim 16

A peptide consisting of the sequence of any one of SEQ ID NO:1-6.

### Claim 17

A peptide having the sequence of any one of SEQ ID NO:7-42 or an inhibitory portion thereof.

### Claim 18

A peptide consisting of the sequence of any one of SEQ ID NO:7-42.
